Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
Lipitor ®
Disaggregation of Revenue [Line Items]
Net sales	1,635.2	1,663.2
Norvasc ®
Disaggregation of Revenue [Line Items]
Net sales	775.1	824.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	623.8	728.5
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	458.9	533.8
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	378.0	391.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	338.1	344.4
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	304.0	309.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	279.6	316.8
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	246.2	284.3
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	195.1	226.0
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	225.5	299.3
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	202.1	161.9
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	179.8	168.0
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	167.9	201.5
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	$ 156.5	$ 185.9